Teleflex Incorporated (TFX) Stock Price & How to Invest

Teleflex Incorporated designs and manufactures single-use medical devices used in critical care and surgery, sold mainly to hospitals through a large disposable-product installed base. After a portfolio overhaul announced in 2025 and executed through 2026, the continuing business reports in three segments: Vascular Access (the Arrow line of central venous and arterial catheters and related kits), Interventional (complex catheters, the MANTA large-bore closure device, intra-aortic balloon pumps, and the newly acquired Biotronik coronary and peripheral range including the ultrathin Orsiro Mission drug-eluting stent, the PK Papyrus covered stent, and the Pantera Lux and Passeo-18 Lux drug-coated balloons), and Surgical (ligation clips, closure systems, and instruments). The businesses being sold, Acute Care, Interventional Urology (home of UroLift), and OEM contract manufacturing, are reported as discontinued operations.

The investment picture is dominated by that transformation rather than by any single product cycle. Teleflex closed the ~EUR 760 million Biotronik vascular intervention acquisition in the first quarter of 2026, which lifted reported revenue growth into the 30% range while pro forma constant currency growth ran near ~5%, and it agreed to sell the three exiting units for ~$2.03 billion gross (~$1.8 billion net of tax), earmarked for a ~$1 billion share repurchase and roughly ~$800 million of debt reduction. Against that, GAAP results swung to a large loss on divestiture-related charges, ~$90 million of stranded costs weigh on 2026, and the company has been run by an interim chief executive since January 2026. The market view generally reduces to whether a focused vascular and surgical portfolio can compound faster than the old conglomerate did, at a valuation that still sits below large-cap medtech peers.

The Acute Care and Interventional Urology sale to Intersurgical drew a Federal Trade Commission second request in March 2026, so that leg of the divestiture carries real timing and completion risk even though the OEM sale cleared. GAAP results are deeply negative on trailing twelve months (a net loss of roughly ~$1 billion) because of divestiture and impairment charges, which makes trailing earnings metrics unusable and forces reliance on adjusted figures. Integration risk from the Biotronik deal is meaningful: coronary stents and drug-coated balloons compete head-on with Abbott, Boston Scientific, Medtronic and Terumo, all of which are larger and have deeper clinical evidence programs. The company is led by an interim chief executive, and a permanent hire could revisit strategy or guidance. Beyond that, hospital procedure volumes, reimbursement pressure, tariffs, currency, and the ~$90 million stranded-cost overhang all bear on whether the 2026 adjusted EPS range of ~$6.25 to ~$6.55 holds.

11 analysts publish price targets on TFX, averaging $149.45 against a $139.70 price as of August 2026, or +7.0%. The published targets run from $138.00 to $160.00, a narrow spread, and the ratings split 5 buy, 8 hold, 0 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TFX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Teleflex Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Biotronik vascular intervention integration. The acquired coronary and peripheral franchise adds Orsiro Mission drug-eluting stents, PK Papyrus covered stents, and the Pantera Lux and Passeo-18 Lux drug-coated balloons to a business that previously sold mostly access and closure devices. The most optimistic published target, $160.00, assumes this works close to its best case.

The case against. The Acute Care and Interventional Urology sale to Intersurgical drew a Federal Trade Commission second request in March 2026, so that leg of the divestiture carries real timing and completion risk even though the OEM sale cleared. The most pessimistic target, $138.00, is roughly what TFX is worth if this bites instead.

Read the full bull and bear case on TFX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Teleflex Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$2.13B (continuing operations)
• Q1 2026 revenue: ~$548M (+32% reported, ~+5% pro forma cc)
• 2026 adjusted EPS guidance: ~$6.25 to ~$6.55
• 2026 pro forma cc revenue growth: ~4.5% to ~5.5%
• Market cap: ~$6.2B
• Forward P/E: ~18x

Trailing P/E is not meaningful because GAAP net income is around negative ~$1 billion on divestiture and impairment charges, so the market prices Teleflex off adjusted EPS and forward estimates instead. At roughly ~$140 the shares sit near the upper end of a ~$100 to ~$144 fifty-two week range, and the forward multiple near ~18x is below where large-cap medtech peers typically trade. Second quarter 2026 results are due in early August 2026, and the first set of clean post-divestiture pro forma financials is the number investors are waiting on.

Other names that sit close to TFX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get TFX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TFX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TFX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Teleflex is a restructuring story first and a vascular growth story second, and the debate is whether the narrower portfolio grows fast enough to earn a higher multiple.

Whether TFX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TFX a buy or a sell?, and where the stock could go from here in the TFX stock forecast.

For income investors, whether TFX pays a dividend and how the payout looks is covered in does TFX pay a dividend? And to weigh TFX against a peer, read the full side-by-side comparisons: TFX vs BAX and TFX vs MMSI.